Literature DB >> 25773659

Prevalence of ankylosing spondylitis in Poland and costs generated by AS patients in the public healthcare system.

A Śliwczyński1, F Raciborski, A Kłak, M Brzozowska, T Czeleko, B Kwiatkowska, T Jędrzejczyk, M Marczak.   

Abstract

The aim of the research was to analyse the prevalence of ankylosing spondylitis (AS) in Poland and to assess the costs generated by AS patients in the system of public health care. The database of national payer-National Health Fund (NHF)-has been analysed. For the analysis, the information has been extracted from IT system about each treated patient with ICD-10 = M45 code as main or coexisting diagnosis included in the mandatory reports from entities of public healthcare service. In the years 2008-2013, from 28,800 to 32,800 persons diagnosed with AS as main or coexisting diagnosis have been registered in NHF database. In 2013, the prevalence amounted to 7.48 for 10,000 persons of general population-the highest in Kujawy-Pomerania province (10.92 per 10,000 inhabitants), Silesia (10.04) and Świętokrzyskie province (9.81). In male patients, this coefficient amounted to 8.91 per 10,000 inhabitants, whereas in female-to 6.15. In 2013, the prevalence for men was the highest in the age group of 60-64 years and for women in the group of 65-69 years. The healthcare expenses related to AS financed by the NHF increased from 13,200 million PLN (6.3 million USD) in 2008 to 72,600 million PLN (21,900 million USD) in 2013. The increase in healthcare expenses related to AS patients in the public healthcare system is significant and noticeable. High regional diversity is also a vital issue. It is necessary to carry out further research on the incidence rate of AS in Polish population.

Entities:  

Mesh:

Year:  2015        PMID: 25773659     DOI: 10.1007/s00296-015-3247-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  12 in total

1.  Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis.

Authors:  Ernst Feldtkeller; Muhammad Asim Khan; Désirée van der Heijde; Sjef van der Linden; Jürgen Braun
Journal:  Rheumatol Int       Date:  2002-09-03       Impact factor: 2.631

Review 2.  Global prevalence of ankylosing spondylitis.

Authors:  Linda E Dean; Gareth T Jones; Alan G MacDonald; Christina Downham; Roger D Sturrock; Gary J Macfarlane
Journal:  Rheumatology (Oxford)       Date:  2013-12-09       Impact factor: 7.580

Review 3.  Ankylosing spondylitis: field in progress.

Authors:  Gleb Slobodin; Itzhak Rosner; Doron Rimar; Nina Boulman; Michael Rozenbaum; Majed Odeh
Journal:  Isr Med Assoc J       Date:  2012-12       Impact factor: 0.892

4.  Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci.

Authors:  S H Laval; A Timms; S Edwards; L Bradbury; S Brophy; A Milicic; L Rubin; K A Siminovitch; D E Weeks; A Calin; B P Wordsworth; M A Brown
Journal:  Am J Hum Genet       Date:  2001-02-27       Impact factor: 11.025

Review 5.  Frequency of rheumatic diseases in Portugal: a systematic review.

Authors:  Teresa Monjardino; Raquel Lucas; Henrique Barros
Journal:  Acta Reumatol Port       Date:  2011 Oct-Dec       Impact factor: 1.290

Review 6.  Ankylosing spondylitis and uveitis: overview.

Authors:  Enéias Bezerra Gouveia; Dório Elmann; Maira Saad de Ávila Morales
Journal:  Rev Bras Reumatol       Date:  2012-10

7.  The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study.

Authors:  Carmen Stolwijk; Ivette Essers; Astrid van Tubergen; Annelies Boonen; Marloes T Bazelier; Marie L De Bruin; Frank de Vries
Journal:  Ann Rheum Dis       Date:  2014-03-21       Impact factor: 19.103

8.  What epidemiology has told us about risk factors and aetiopathogenesis in rheumatic diseases.

Authors:  Jacqueline E Oliver; Alan J Silman
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

9.  Aortic root disease and valve disease associated with ankylosing spondylitis.

Authors:  C A Roldan; J Chavez; P W Wiest; C R Qualls; M H Crawford
Journal:  J Am Coll Cardiol       Date:  1998-11       Impact factor: 24.094

10.  Prevalence of diagnosis and direct treatment costs of back disorders in 644,773 children and youths in Germany.

Authors:  Elke B Ochsmann; Carlos L Escobar Pinzón; Stephan Letzel; Thomas Kraus; Martina Michaelis; Eva Muenster
Journal:  BMC Musculoskelet Disord       Date:  2010-08-28       Impact factor: 2.362

View more
  5 in total

1.  Prevalence of axial spondyloarthritis in Poland.

Authors:  Małgorzata Tłustochowicz; Melania Brzozowska; Waldemar Wierzba; Filip Raciborski; Brygida Kwiatkowska; Witold Tłustochowicz; Andrzej Jacyna; Michał Marczak; Bartłomiej Kisiel; Andrzej Śliwczyński
Journal:  Rheumatol Int       Date:  2019-12-04       Impact factor: 2.631

2.  Association of GSTM1, GSTT1, GSTP1-ILE105VAL and ACE I/D polymorphisms with ankylosing spondylitis.

Authors:  Esra Erkol İnal; Orhan Görükmez; Selma Eroğlu; Özlem Görükmez; Özlem Solak; Ali Topak; Tahsin Yakut
Journal:  Rheumatol Int       Date:  2015-07-18       Impact factor: 2.631

3.  Disease activity, quality of life and indirect costs of reduced productivity at work, generated by Polish patients with ankylosing spondylitis.

Authors:  Paweł Kawalec; Krzysztof Malinowski
Journal:  Reumatologia       Date:  2016-02-11

4.  Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system - the case of Poland.

Authors:  Filip Raciborski; Andrzej Śliwczyński; Anna Kłak; Brygida Kwiatkowska; Melania Brzozowska; Małgorzata Tłustochowicz
Journal:  Reumatologia       Date:  2016-12-30

5.  Epidemiology and direct costs of atopic dermatitis in Poland based on the National Health Fund register (2008-2017).

Authors:  Filip Raciborski; Karina Jahnz-Rozyk; Anna Kłak; Adam J Sybilski; Aleksandra M Grąbczewska; Melania Brzozowska; Andrzej M Śliwczyñski
Journal:  Postepy Dermatol Alergol       Date:  2018-10-19       Impact factor: 1.837

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.